Drawing for AEVI GENOMIC MEDICINE

USPTO serial 87243174

AEVI GENOMIC MEDICINE

Reviewed by CopyMark Law Group

Status 606
Filing date
Status date
Registration date
—
Examiner
CHISOLM, KEVON
Law office
INTENT TO USE SECTION

What this means

This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.

Need help with AEVI GENOMIC MEDICINE?

If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.

Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.

Owner

Attorney of record

The USPTO lists this attorney as the applicant's representative for correspondence on this application.

Monica Riva Talley

MONICA RIVA TALLEY STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.1100 NEW YORK AVENUE, N.W.WASHINGTON, DC 20005UNITED STATES

Goods and services

ClassDescriptionStatusFirst use
001Reagents for research purposes; assays for research purposesACTIVE—
005Pharmaceutical products, namely, treatments for pediatric onset and rare and orphan disorders; biological and chemical preparations for medical and veterinary use; antibodies for medical and veterinary use; proteins, enzymes, and peptides for medical and veterinary use; small molecule drugs for use in treatments for pediatric onset and rare and orphan disorders; reagents for medical use; diagnostic reagents and diagnostic assays for medical use; therapeutic agents for use in treatments for pediatric onset and rare and orphan disorders; immunotherapeutics and immunologics for use in treatments for pediatric onset and rare and orphan disorders; viral, retroviral, and non-viral vectors for use in treatments for pediatric onset and rare and orphan disorders; vaccines; adjuvants; pharmaceutical preparations for the treatment of rare and difficult-to-treat diseases; biological materials, namely, genetically modified autologous tissue implants, intended to produce proteins for therapeutic usesACTIVE—
010Medical devices and instruments for genetically modifying tissueACTIVE—
042Medical research; pharmaceutical drug development services; testing, inspection, research, or development of pharmaceutical preparations for gene therapyACTIVE—
044Medical services, namely, harvesting tissue from a patient, genetically modifying that tissue and then reintroducing it into the same patient for therapeutic purposes; medical servicesACTIVE—

Related trademarks

CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.

Prosecution history

Latest event (MAB6): The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.

DateCodeEventWhat it means
Jan 27, 2020MAB6ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jan 27, 2020ABN6ABANDONMENT - NO USE STATEMENT FILEDThe intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window.
Jun 29, 2019EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 27, 2019EX4GSOU EXTENSION 4 GRANTED—
Jun 27, 2019EXT4SOU EXTENSION 4 FILED—
Jun 27, 2019EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Dec 29, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 27, 2018EX3GSOU EXTENSION 3 GRANTED—
Dec 27, 2018EXT3SOU EXTENSION 3 FILED—
Dec 27, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 7, 2018EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Jun 5, 2018EX2GSOU EXTENSION 2 GRANTED—
Jun 5, 2018EXT2SOU EXTENSION 2 FILED—
Jun 5, 2018EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 5, 2018TCCATEAS CHANGE OF CORRESPONDENCE RECEIVED—
Dec 15, 2017EXRANOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED—
Dec 13, 2017EX1GSOU EXTENSION 1 GRANTED—
Dec 13, 2017EXT1SOU EXTENSION 1 FILED—
Dec 13, 2017EEXTSOU TEAS EXTENSION RECEIVEDThe applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use.
Jun 27, 2017NOAMNOA E-MAILED - SOU REQUIRED FROM APPLICANTA Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date.
May 2, 2017CHANAPPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED—
May 2, 2017COARTEAS CHANGE OF OWNER ADDRESS RECEIVED—
May 2, 2017NPUBOFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED—
May 2, 2017PUBOPUBLISHED FOR OPPOSITIONYour mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance.
Apr 12, 2017NONPNOTIFICATION OF NOTICE OF PUBLICATION E-MAILED—
Apr 5, 2017ASGNAUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP—
Mar 28, 2017PREVLAW OFFICE PUBLICATION REVIEW COMPLETED—
Mar 23, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 23, 2017ZZZXPREVIOUS ALLOWANCE COUNT WITHDRAWN—
Mar 21, 2017CNSAAPPROVED FOR PUB - PRINCIPAL REGISTER—
Mar 21, 2017XAECEXAMINER'S AMENDMENT ENTERED—
Mar 21, 2017ALIEASSIGNED TO LIE—
Mar 20, 2017GNENNOTIFICATION OF EXAMINERS AMENDMENT E-MAILED—
Mar 20, 2017GNEAEXAMINERS AMENDMENT E-MAILED—
Mar 20, 2017CNEAEXAMINERS AMENDMENT -WRITTEN—
Mar 3, 2017GNRNNOTIFICATION OF NON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 3, 2017GNRTNON-FINAL ACTION E-MAILEDA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Mar 3, 2017CNRTNON-FINAL ACTION WRITTENA non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application.
Feb 27, 2017DOCKASSIGNED TO EXAMINER—
Nov 28, 2016NWOSNEW APPLICATION OFFICE SUPPLIED DATA ENTERED—
Nov 24, 2016NWAPNEW APPLICATION ENTERED—

Frequently asked questions

Related guidance